Ganirelix and the Prevention of Premature Luteinizing Hormone Surges

Overview

Journal F S Rep

Specialty Reproductive Medicine

Date 2023 May 24

PMID 37223764

Authors

Bernadette Mannaerts

Affiliations

Soon will be listed here.

Abstract

Ganirelix is a gonadotropin-releasing hormone (GnRH) antagonist with high antagonistic activity that blocks the GnRH receptor by competitive binding. A daily dose of 0.25 mg of ganirelix was sel5ected after a phase II study because it was the minimal, effective daily dose to prevent premature luteinizing hormone surges and this dose yielded the highest ongoing pregnancy rate per started cycle. After subcutaneous administration, ganirelix is rapidly absorbed, reaching peak levels within 1-2 hours (t), and has a high absolute bioavailability (>90%). Prospective, comparative studies have demonstrated the advantages of GnRH antagonists over long GnRH agonist treatment in assisted reproduction, including the immediate reversibility of drug effects, a requirement for less follicle-stimulating hormone, a shortened duration of stimulation, a reduced incidence of ovarian hyperstimulation syndrome, and reduced patient burden. Combined analyses concluded that in the general in vitro fertilization population, there is a trend for a slightly lower ongoing pregnancy rate and a lower risk of ovarian hyperstimulation syndrome that is largely eliminated when considering triggering with GnRH agonist instead of human chorionic gonadotropin. Regardless of all the research, it is still not fully elucidated why the long GnRH agonist protocol has a trend for higher pregnancy rates after fresh transfer of the same number of good-quality embryos.

Citing Articles

GnRH Peptide Antagonist: Comparative Analysis of Chemistry and Formulation with Implications for Clinical Safety and Efficacy.

Patel S, Saxena B, Mehta P, Niazi S Pharmaceuticals (Basel). 2025; 18(1).

PMID: 39861098 PMC: 11768417. DOI: 10.3390/ph18010036.

The role of elagolix in ovulation suppression during controlled ovarian stimulation: a retrospective cohort study.

Soliman D, Naoom R, Zaied M, Soliman S F S Rep. 2025; 5(4):356-362.

PMID: 39781082 PMC: 11705702. DOI: 10.1016/j.xfre.2024.06.006.

References

Kol S . Luteolysis induced by a gonadotropin-releasing hormone agonist is the key to prevention of ovarian hyperstimulation syndrome. Fertil Steril. 2004; 81(1):1-5. DOI: 10.1016/j.fertnstert.2003.05.032. View

Devroey P, Polyzos N, Blockeel C . An OHSS-Free Clinic by segmentation of IVF treatment. Hum Reprod. 2011; 26(10):2593-7. DOI: 10.1093/humrep/der251. View

Oberye J, Mannaerts B, Huisman J, Timmer C . Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Antagon/Orgalutran). Part II. Dose-proportionality and gonadotropin suppression after multiple doses of ganirelix in healthy female volunteers. Fertil Steril. 1999; 72(6):1006-12. DOI: 10.1016/s0015-0282(99)00414-8. View

Al-Inany H, Youssef M, Ayeleke R, Brown J, Lam W, Broekmans F . Gonadotrophin-releasing hormone antagonists for assisted reproductive technology. Cochrane Database Syst Rev. 2016; 4:CD001750. PMC: 8626739. DOI: 10.1002/14651858.CD001750.pub4. View

Borm G, Mannaerts B . Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial..... Hum Reprod. 2000; 15(7):1490-8. DOI: 10.1093/humrep/15.7.1490. View

Oberye J, Mannaerts B, Kleijn H, Timmer C . Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Antagon/Orgalutran). Part I. Absolute bioavailability of 0.25 mg of ganirelix after a single subcutaneous injection in healthy female volunteers. Fertil Steril. 1999; 72(6):1001-5. DOI: 10.1016/s0015-0282(99)00413-6. View

Lambalk C, Banga F, Huirne J, Toftager M, Pinborg A, Homburg R . GnRH antagonist versus long agonist protocols in IVF: a systematic review and meta-analysis accounting for patient type. Hum Reprod Update. 2017; 23(5):560-579. DOI: 10.1093/humupd/dmx017. View

Nyboe Andersen A, Nelson S, Fauser B, Garcia-Velasco J, Klein B, Arce J . Individualized versus conventional ovarian stimulation for in vitro fertilization: a multicenter, randomized, controlled, assessor-blinded, phase 3 noninferiority trial. Fertil Steril. 2016; 107(2):387-396.e4. DOI: 10.1016/j.fertnstert.2016.10.033. View

Kol S, Lightman A, Hillensjo T, Devroey P, Fauser B, Tarlatzis B . High doses of gonadotrophin-releasing hormone antagonist in in-vitro fertilization cycles do not adversely affect the outcome of subsequent freeze-thaw cycles. Hum Reprod. 1999; 14(9):2242-4. DOI: 10.1093/humrep/14.9.2242. View

10.

. Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation. Hum Reprod. 2001; 16(4):644-51. DOI: 10.1093/humrep/16.4.644. View

11.

Frattarelli J, Hillensjo T, Broekmans F, Witjes H, Elbers J, Gordon K . Clinical impact of LH rises prior to and during ganirelix treatment started on day 5 or on day 6 of ovarian stimulation. Reprod Biol Endocrinol. 2013; 11:90. PMC: 3847921. DOI: 10.1186/1477-7827-11-90. View

12.

. A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant.... Hum Reprod. 1998; 13(11):3023-31. View

13.

Humaidan P, Alsbjerg B . GnRHa trigger for final oocyte maturation: is HCG trigger history?. Reprod Biomed Online. 2014; 29(3):274-80. DOI: 10.1016/j.rbmo.2014.05.008. View

14.

Tarlatzis B, Fauser B, Kolibianakis E, Diedrich K, Rombauts L, Devroey P . GnRH antagonists in ovarian stimulation for IVF. Hum Reprod Update. 2006; 12(4):333-40. DOI: 10.1093/humupd/dml001. View

15.

Itskovitz-Eldor J, Kol S, Mannaerts B . Use of a single bolus of GnRH agonist triptorelin to trigger ovulation after GnRH antagonist ganirelix treatment in women undergoing ovarian stimulation for assisted reproduction, with special reference to the prevention of ovarian hyperstimulation.... Hum Reprod. 2000; 15(9):1965-8. DOI: 10.1093/humrep/15.9.1965. View

16.

Fauser B, de Jong D, Olivennes F, Wramsby H, Tay C, Itskovitz-Eldor J . Endocrine profiles after triggering of final oocyte maturation with GnRH agonist after cotreatment with the GnRH antagonist ganirelix during ovarian hyperstimulation for in vitro fertilization. J Clin Endocrinol Metab. 2002; 87(2):709-15. DOI: 10.1210/jcem.87.2.8197. View

17.

Toftager M, Bogstad J, Bryndorf T, Lossl K, Roskaer J, Holland T . Risk of severe ovarian hyperstimulation syndrome in GnRH antagonist versus GnRH agonist protocol: RCT including 1050 first IVF/ICSI cycles. Hum Reprod. 2016; 31(6):1253-64. DOI: 10.1093/humrep/dew051. View

18.

Fluker M, Grifo J, Leader A, Levy M, Meldrum D, Muasher S . Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation. Fertil Steril. 2001; 75(1):38-45. DOI: 10.1016/s0015-0282(00)01638-1. View

19.

Raga F, Casan E, Kruessel J, Wen Y, Bonilla-Musoles F, Polan M . The role of gonadotropin-releasing hormone in murine preimplantation embryonic development. Endocrinology. 1999; 140(8):3705-12. DOI: 10.1210/endo.140.8.6899. View

20.

Simon C, Oberye J, Bellver J, Vidal C, Bosch E, Horcajadas J . Similar endometrial development in oocyte donors treated with either high- or standard-dose GnRH antagonist compared to treatment with a GnRH agonist or in natural cycles. Hum Reprod. 2005; 20(12):3318-27. DOI: 10.1093/humrep/dei243. View